Betta Pharmaceutical announced that the BPI-572270 capsule clinical trial application declared by Hangzhou Jingyao Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, was approved by the US FDA. The application number is IND 184065 and is intended for advanced solid tumors. In January 2026, clinical trials of the drug were approved by the State Drug Administration, and it is currently in the phase of dose climbing and dose backfilling.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.